Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis
- PMID: 26254836
- PMCID: PMC4586395
- DOI: 10.1016/j.jpeds.2015.06.062
Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis
Abstract
Objective: To investigate the relationship between abdominal ultrasound findings and demographic, historical, and clinical features in children with cystic fibrosis (CF).
Study design: Children age 3-12 years with CF without known cirrhosis, were enrolled in a prospective, multicenter study of ultrasound to predict hepatic fibrosis. Consensus ultrasound patterns were assigned by 3 radiologists as normal, heterogeneous, homogeneous, or cirrhosis. Data were derived from direct collection and US or Toronto CF registries. χ(2) or ANOVA were used to compare variables among ultrasound groups and between normal and abnormal. Logistic regression was used to study risk factors for having abnormal ultrasound.
Results: Findings in 719 subjects were normal (n = 590, 82.1%), heterogeneous (64, 8.9%), homogeneous (41, 5.7%), and cirrhosis (24, 3.3%). Cirrhosis (P = .0004), homogeneous (P < .0001), and heterogeneous (P = .03) were older than normal. More males were heterogeneous (P = .001). More heterogeneous (15.0%, P = .009) and cirrhosis (25.0%, P = .005) had CF-related diabetes or impaired glucose tolerance vs normal (5.4%). Early infection with Pseudomonas aeruginosa (<2 years old) was associated with a lower risk (OR 0.42, P = .0007) of abnormal. Ursodeoxycholic acid use (OR 3.69, P < .0001) and CF-related diabetes (OR 2.21, P = .019) were associated with increased risk of abnormal.
Conclusions: Unsuspected cirrhosis is seen in 3.3% of young patients with CF, heterogeneous in 8.9%. Abnormal ultrasound is associated with CF-related diabetes, and early P aeruginosa is associated with normal ultrasound. Prospective assessment of these risk factors may identify potential interventional targets.
Trial registration: ClinicalTrials.gov: NCT01144507.
Copyright © 2015 Elsevier Inc. All rights reserved.
Figures
References
-
- Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28(Suppl 1):S1–13. - PubMed
-
- Colombo C, Russo MC, Zazzeron L, Romano G. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2006;43(Suppl 1):S49–55. - PubMed
-
- Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151–1158. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UL1 TR000150/TR/NCATS NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- P30 DK089507/DK/NIDDK NIH HHS/United States
- DK062453/DK/NIDDK NIH HHS/United States
- U01 DK103135/DK/NIDDK NIH HHS/United States
- UL1TR001108/TR/NCATS NIH HHS/United States
- U01 DK062436/DK/NIDDK NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- DK084536-07/DK/NIDDK NIH HHS/United States
- U01 DK084575/DK/NIDDK NIH HHS/United States
- U01 DK084536/DK/NIDDK NIH HHS/United States
- UL1 TR001425/TR/NCATS NIH HHS/United States
- UL1 TR000077/TR/NCATS NIH HHS/United States
- UL1 TR000423/TR/NCATS NIH HHS/United States
- U01 DK062500/DK/NIDDK NIH HHS/United States
- U01 DK062453/DK/NIDDK NIH HHS/United States
- KL2 TR001426/TR/NCATS NIH HHS/United States
- KL2 TR000078/TR/NCATS NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- DK62456/DK/NIDDK NIH HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- U01 DK062456/DK/NIDDK NIH HHS/United States
- RR025014/RR/NCRR NIH HHS/United States
- UL1 TR 001079/TR/NCATS NIH HHS/United States
- U24 DK062456/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
